As chronic liver disease progresses, an imbalance occurs betweensynthesis and breakdown of extracellular matrix (ECM).Matrix metalloproteinases (MMPs) are involved in degrading ECM whiletissue inhibitors of metalloproteinases (TIMPs) prevent their fibrolyticaction.Transforming growth factor β1 (TGF-β1) is a key mediator of liverfibrogenesis.The aim of this study is evaluating TIMPs & TGF- β1 as fibrogenicseromarkers in comparison to histopathological examination of liverbiopsy in HCV patients and comparing these fibrogenic seromarkers inHCV patients versus HBV patients.Methods: commercially available ELISA assays were used tostudy circulating levels of TIMP-I & TGF-β1 in patients with chronichepatitis C n=50 patients and 20 patients with chronic hepatitis B andtwenty individuals as healthy control group. Hepatic histology wasevaluated using METAVIR scoring system.Results: In HCV patients TIMP-I was elevated with progress ofliver disease and those levels correlated closely with the degree of liverfibrosis and to a lesser extent with the degree of necorinflammation.TIMP-I detected fibrosis with a sensitivity of 100% the specificitywas 87%.As regards TGF β1 had negative correlation with METAVIR scorein HCV patients.In comparison between HCV & HBV patients there was significantincrease in serum level of TIMP-I in HCV patients than HBV patients, onthe other hand there is significant decrease of serum level TGF- β1 inHCV patients than HBV patients.Conclusion: TIMP-I is a reliable predictor to detect advancedfibrosis. TIMP-1 was increased significantly in HCV patients incomparison to HBV patients. But TGF-β1 was decreased significantly inHCV patients in comparison to HBV patients.